Stomach Scarring Cuts H. Pylori Cure Rates in Half, New Study Finds

Roughly three-quarters of patients treated for Helicobacter pylori infection at a Chinese hospital cleared the bacteria after a standard first-line regimen, but that headline number hides a striking split: patients with the most extensive stomach-lining damage succeeded at roughly half the rate of everyone else. A retrospective cohort study published in Frontiers in Medicine by D. Wang, X. Ding, and A.W. Ding suggests that a simple endoscopic grading system, one that takes only minutes to apply, may reliably flag patients who are likely to fail first-line therapy before treatment even begins.

Open-Type Gastric Atrophy Predicts H. pylori Eradication Failure

The study enrolled 154 patients at Wuhan Fourth Hospital between November 2021 and November 2025, all of whom tested positive on a urea breath test, had confirmed chronic atrophic gastritis, and received a bismuth-containing quadruple regimen. The overall eradication rate came to 76.6%, respectable by current standards but not exceptional. When researchers separated patients by atrophy severity using the Kimura-Takemoto classification, a well-validated endoscopic grading system that scores damage from mild closed-type (C1) through severe open-type (O3), the gap was striking. Patients with closed-type atrophy cleared the infection 83.6% of the time (107 of 128 patients). Patients with open-type atrophy succeeded only 42.3% of the time, just 11 of 26 patients.

Multivariate logistic regression confirmed that open-type atrophy was independently associated with eradication failure, with an odds ratio of 8.287 (95% CI: 3.150 to 21.804, P<0.001). Age and body weight were adjusted for in the analysis, so the signal is not simply a proxy for older or frailer patients.

Why Severe Stomach Atrophy Changes the Antibiotic Environment

Gastric atrophy is not merely a cancer-risk marker. As the stomach lining degrades, the local environment shifts in ways that may directly compromise how antibiotics work. Proton pump inhibitors, a cornerstone of H. pylori regimens, work by suppressing acid secretion, but a stomach that has already lost most of its acid-producing mucosa behaves differently from a healthy one. Drug distribution, local pH, and bacterial density can all change in ways that reduce antibiotic exposure at the mucosal surface where the bacteria live.

Open-type atrophy, as defined by the Kimura-Takemoto visual endoscopic classification, extends beyond the cardia to the greater curvature of the stomach, indicating widespread mucosal loss. Closed-type atrophy, by contrast, is confined to a smaller region around the lesser curvature. Studies have shown that the Kimura-Takemoto system correlates well with histological atrophy scores from biopsy, meaning the endoscopic grade reflects genuine tissue-level damage rather than a rough visual estimate.

How the Wuhan Cohort Was Assembled and Graded

The team reviewed high-definition white-light gastroscopy images taken within 28 days before therapy for each patient. Two independent endoscopists graded the atrophy, reducing the subjectivity that can plague visual classification. The primary endpoint was straightforward: a positive follow-up urea breath test at least four weeks after completing therapy counted as eradication failure. The design is retrospective, which carries the usual limitations, but the consecutive enrollment from a single center over four years and the rigorous imaging review lend the findings reasonable credibility for an exploratory study of this kind.

All patients received the same first-line regimen, a bismuth-containing quadruple therapy, which rules out differential treatment as an explanation for the outcome gap between atrophy grades.

Key Limitations Before Changing Clinical Practice

The sample size is modest. Twenty-six patients in the open-type group is enough to generate a statistically robust odds ratio, but not enough to answer finer questions: does the failure risk differ across O1, O2, and O3 sub-grades, or does any degree of open-type atrophy carry similar risk? The study was also conducted at a single Chinese center, and H. pylori strain distributions, local antibiotic resistance patterns, and patient demographics may not generalize to other populations.

It is worth noting that even successful eradication does not fully reverse atrophic damage. Research has shown that histological atrophy scores can improve after eradication while intestinal metaplasia, the more advanced precancerous lesion, tends to persist. The Kimura-Takemoto classification can identify individuals who remain at elevated cancer risk even after H. pylori is cleared, which underscores why accurate grading matters beyond just predicting treatment response.

What Clinicians Might Do Differently for Open-Type Atrophy Patients

The authors are specific about the practical implication: they advise caution with clarithromycin-containing quadruple regimens for patients whose endoscopy reveals open-type atrophy. That is a narrower recommendation than abandoning bismuth-based therapy altogether, and it aligns with broader concerns about clarithromycin resistance undermining standard regimens in high-resistance regions.

If the findings hold in larger, prospective studies, gastroenterologists could use a pre-treatment endoscopy not only to screen for cancer precursors but also to triage H. pylori patients toward more aggressive or tailored eradication strategies from the outset. For a patient facing an 8-fold higher odds of failure with a standard regimen, the case for choosing a salvage-level protocol upfront becomes straightforward. The next step is a prospective validation, ideally across multiple centers and with sub-grade analysis within the open-type category, to determine exactly where the threshold lies and whether certain regimens outperform others in this high-risk group.

Evidence rating

EMERGING — 76/100

Caveats:

• Retrospective single-center design limits generalizability — all patients were hospitalized at one hospital in Wuhan, China.
• The open-type atrophy group was small (n=26), which may inflate the apparent effect size.
• Funding source was not disclosed, so independent verification of the research context is not possible.
• Association does not establish mechanism — why open-type atrophy reduces antibiotic efficacy (e.g., altered drug distribution, gastric pH, bacterial load) is not fully characterized.
• Results have not yet been independently replicated in a prospective or multi-center study.

Single-center retrospective cohort study (n=154) conducted in China. Finds a statistically significant association between Kimura-Takemoto open-type gastric atrophy and H. pylori eradication failure, but cannot establish causation. The open-type subgroup was small (n=26), which limits precision, and the findings have not been independently replicated in a prospective or multi-center cohort.